Journal
NATURE GENETICS
Volume 42, Issue 2, Pages 181-U124Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ng.518
Keywords
-
Categories
Funding
- National Cancer Institute Office of Cancer Genomics
- National Cancer Institute of Canada (NCIC) Terry Fox Foundation [016003]
- The Terry Fox Foundation [019001]
- NCIC [019005]
- Michael Smith Foundation for Health Research (MSFHR) [ST-DF-01793]
- The Leukemia & Lymphoma Society
- MSFHR
- BC Cancer Foundation
- Lion's Club International
- National Cancer Institute
- National Institutes of Health [NO1-CO-12400]
Ask authors/readers for more resources
Follicular lymphoma (FL) and the GCB subtype of diffuse large B-cell lymphoma (DLBCL) derive from germinal center B cells(1). Targeted resequencing studies have revealed mutations in various genes encoding proteins in the NF-kappa B pathway(2,3) that contribute to the activated B-cell (ABC) DLBCL subtype, but thus far few GCB-specific mutations have been identified(4). Here we report recurrent somatic mutations affecting the polycomb-group oncogene(5) EZH2, which encodes a histone methyltransferase responsible for trimethylating Lys27 of histone H3 (H3K27). After the recent discovery of mutations in KDM6A (UTX), which encodes the histone H3K27me3 demethylase UTX, in several cancer types(6), EZH2 is the second histone methyltransferase gene found to be mutated in cancer. These mutations, which result in the replacement of a single tyrosine in the SET domain of the EZH2 protein (Tyr641), occur in 21.7% of GCB DLBCLs and 7.2% of FLs and are absent from ABC DLBCLs. Our data are consistent with the notion that EZH2 proteins with mutant Tyr641 have reduced enzymatic activity in vitro.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available